目的 比較阿戈美拉汀與選擇性五羥色胺再攝取抑制劑（SSRIs）治療抑郁癥的療效和安全性。方法 計(jì)算機(jī)檢索PubMed、EMBase、Cochrane圖書(shū)館、中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（CBM）和萬(wàn)方數(shù)據(jù)庫(kù)，篩選阿戈美拉汀與SSRIs相比較治療抑郁癥的隨機(jī)對(duì)照試驗(yàn)（RCT），比較阿戈美拉汀與SSRIs的療效與不良反應(yīng)（ADR）。檢索時(shí)限從建庫(kù)至2019年4月，采用RevMan 5.3統(tǒng)計(jì)軟件進(jìn)行Meta-分析。結(jié)果 共納入12項(xiàng)RCTs，計(jì)3 292例患者。Meta-分析結(jié)果顯示阿戈美拉汀與SSRIs治療后總有效率、治愈率比較，差異無(wú)統(tǒng)計(jì)學(xué)意義；阿戈美拉汀較SSRIs惡心的發(fā)生率低，差異有統(tǒng)計(jì)學(xué)意義[RR=0.58，95% CI（0.47，0.72），P<0.000 01]；致失眠發(fā)生率低，差異有統(tǒng)計(jì)學(xué)意義[RR=0.47，95% CI（0.32，0.69），P=0.000 1]；致腹瀉、便秘及多汗差異均有統(tǒng)計(jì)學(xué)意義，其他ADR發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 阿戈美拉汀治療抑郁癥與SSRIs療效相當(dāng)、安全性尚可，致ADR發(fā)生率不比SSRIs的高。

Objective To systematically review the effect and safty for the treatment of depression comparing between agomelatin and selective serotonin reuptake inhibitors(SSRIs),and provide evidence-based reference for clinical treatment. Methods Retrieved from PubMed, EMBase, Cochrane Library, CBM, CNKI Database and VIP Database, randomized controlled trials (RCT) about the effect and safety for the treatment of depression comparing between agomelatin and SSRIs were collected,the retrieval period was up to April 2019 and Meta-analysis was performed by using Revman 5.3 software after data extracting. Results Totally 12 RCTs were enrolled, involving 3 292 patients. Results of Meta-analysis showed that there were no significant differences between agomelatin and SSRIs on response and remission rate. The incidence of nausea caused by agomelatin group were lower than SSRIs group[RR=0.58, 95% CI(0.47, 0.72), P<0.000 01],the incidence of insomnia caused by agomelatin group were lower than SSRIs group[RR=0.47, 95% CI(0.32, 0.69), P=0.000 1], there was significant difference in diarrhea, constipation. And hyperhidrosis between 2 groups. Conclusion The effect of agomelatine was similar to SSRIs and the safety was generally acceptable, there were no higher incidence of adverse reactions for the treatment of depression compared with SSRIs.